



ASX / Nasdaq Media Release

17 February 2009

PHARMAXIS BUILDS SENIOR MANAGEMENT TEAM

Pharmaceutical company Pharmaxis (ASX:PXS, Nasdaq:PXSL) today announced that it had appointed Dr Howard Fox to its senior management team in the position of Chief Medical Officer. Dr Fox will assume responsibility for regulatory affairs, pharmacovigilance and medical affairs. Clinical Operations will continue to report to the Medical Director, Dr Brett Charlton.

Dr Fox has more than 15 years experience in the international pharmaceutical industry, the last ten of which has been in respiratory product development. He was most recently with Novartis as a Global Brand Medical Director and previously held the positions of Senior Clinical Research Physician and Principle Medical Expert for Novartis.

Dr Alan Robertson, Pharmaxis Chief Executive Officer said: "The appointment of Howard Fox provides the international regulatory and pharmacovigilance experience necessary for Pharmaxis to bring Bronchitol successfully and rapidly to the market and we are very much looking forward to his contribution."

Dr Fox who has just relocated from the United Kingdom will be based at the company's head office in Sydney.

- ends -

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

RELEASED THROUGH:

Australia:

Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma. Founded in 1998, Pharmaxis is listed on the Australian Securities Exchange (symbol PXS), and on NASDAQ Global Market (symbol PXSL). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
